Close

bluebird bio (BLUE) to Present New Data from Three LentiGlobin Studies at ASH

Go back to bluebird bio (BLUE) to Present New Data from Three LentiGlobin Studies at ASH

bluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting

November 3, 2016 9:01 AM EDT

Data from the Northstar (HGB-204) study of LentiGlobin drug product in transfusion-dependent -thalassemia (TDT) show that all five patients with non-0/0 genotypes and 12 months of follow-up remained free of transfusions, and patients with 0/0 genotypes and 12 months of follow-up (n=5) had a median reduction in transfusion volume of 60%

The median HbAT87Q level at six months in Northstar was 4.7 g/dl across all genotypes, and levels were generally sustained over the second year of follow-up

All patients with TDT from the HGB-205 study remained free of transfusions,... More